MX354725B - Metodo de tratamiento de una enfermedad proliferativa. - Google Patents

Metodo de tratamiento de una enfermedad proliferativa.

Info

Publication number
MX354725B
MX354725B MX2014005726A MX2014005726A MX354725B MX 354725 B MX354725 B MX 354725B MX 2014005726 A MX2014005726 A MX 2014005726A MX 2014005726 A MX2014005726 A MX 2014005726A MX 354725 B MX354725 B MX 354725B
Authority
MX
Mexico
Prior art keywords
treating
proliferative disease
serine
kinase inhibitor
threonine kinase
Prior art date
Application number
MX2014005726A
Other languages
English (en)
Spanish (es)
Other versions
MX2014005726A (es
Inventor
Stuart Darrin
Das Thakur Meghna
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014005726A publication Critical patent/MX2014005726A/es
Publication of MX354725B publication Critical patent/MX354725B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014005726A 2011-11-11 2012-11-09 Metodo de tratamiento de una enfermedad proliferativa. MX354725B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558619P 2011-11-11 2011-11-11
PCT/US2012/064269 WO2013070996A1 (en) 2011-11-11 2012-11-09 Method of treating a proliferative disease

Publications (2)

Publication Number Publication Date
MX2014005726A MX2014005726A (es) 2014-05-28
MX354725B true MX354725B (es) 2018-03-16

Family

ID=47279036

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005726A MX354725B (es) 2011-11-11 2012-11-09 Metodo de tratamiento de una enfermedad proliferativa.

Country Status (10)

Country Link
US (1) US11007194B2 (OSRAM)
EP (1) EP2776037B1 (OSRAM)
JP (1) JP6150813B2 (OSRAM)
CN (2) CN108542906A (OSRAM)
AU (1) AU2012335663B2 (OSRAM)
BR (1) BR112014011223A8 (OSRAM)
CA (1) CA2855243C (OSRAM)
MX (1) MX354725B (OSRAM)
RU (1) RU2622015C2 (OSRAM)
WO (1) WO2013070996A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
AU2013299841B8 (en) * 2012-08-07 2017-01-05 Array Biopharma Inc. Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
WO2017210538A1 (en) * 2016-06-03 2017-12-07 Giordano Caponigro Pharmaceutical combinations
WO2018107146A1 (en) * 2016-12-11 2018-06-14 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of braf mutant cancers
CN110256408B (zh) * 2018-07-12 2022-03-22 深圳市塔吉瑞生物医药有限公司 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
CA3163703A1 (en) * 2020-01-07 2021-07-15 Steve Kelsey Shp2 inhibitor dosing and methods of treating cancer
JP7312335B2 (ja) 2020-06-09 2023-07-20 アレイ バイオファーマ インコーポレイテッド Ｂｒａｆ関連疾患および障害を処置するための４－オキソ－３，４－ジヒドロキナゾリノン化合物
CA3257280A1 (en) 2022-05-25 2023-11-30 Msd International Gmbh COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION
ES3035530T3 (en) 2023-03-09 2025-09-04 Minneamrita Therapeutics Llc Drug combination for the treatment of stomach cancer
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP1000055A1 (en) 1997-05-22 2000-05-17 G.D. Searle & Co. SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
MXPA04003878A (es) 2001-10-25 2004-07-08 Novartis Ag Combinaciones que comprenden un inhibidor selectivo de cicloxigenasa-2.
ATE374753T1 (de) 2001-12-21 2007-10-15 Vernalis Cambridge Ltd 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
WO2005027972A2 (en) 2003-09-23 2005-03-31 Novartis Ag Combination of a vegf receptor inhibitor with a chemotherapeutic agent
EP1692113B1 (en) 2003-11-14 2017-09-27 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
RU2006128788A (ru) 2004-01-09 2008-02-20 Новартис АГ (CH) Производные фенил[4-(3-фенил-1н-пиразол-4-ил)пиримидин-2-ил] амина в качестве igf-1r ингибиторов
CA2567662C (en) 2004-06-10 2012-11-27 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2006102079A1 (en) 2005-03-17 2006-09-28 Novartis Ag N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
US20070099856A1 (en) * 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
AU2006279794B2 (en) 2005-08-12 2011-04-07 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
JP2009504796A (ja) 2005-08-22 2009-02-05 ノバルティス アクチエンゲゼルシャフト ｐＨ依存性薬剤化合物、ｐＨ調整剤および遅延剤を含む医薬組成物
WO2007024843A2 (en) 2005-08-26 2007-03-01 Smithkline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
JP2009530261A (ja) 2006-03-16 2009-08-27 ファイザー・プロダクツ・インク ピラゾール化合物
EP2004165A2 (en) 2006-04-05 2008-12-24 Novartis Pharma AG Synergistic combinations of anticancer agents for treating cancer
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
CN101522661A (zh) 2006-10-02 2009-09-02 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CN101522026A (zh) 2006-10-06 2009-09-02 Irm责任有限公司 蛋白激酶抑制剂及其应用方法
EP2120900A2 (en) 2007-02-15 2009-11-25 Novartis AG Combination of lbh589 with other therapeutic agents for treating cancer
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
KR20100038119A (ko) 2007-08-01 2010-04-12 화이자 인코포레이티드 피라졸 화합물 및 ｒａｆ 억제제로서 이의 용도
BRPI0818340A2 (pt) 2007-10-19 2015-04-22 Abbott Gmbh & Co Kg Produto de dispersão sólida de fármacos baseados em n-aril uréia
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
KR20130040258A (ko) 2008-03-21 2013-04-23 노파르티스 아게 신규한 헤테로시클릭 화합물 및 그의 용도
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
HRP20120577T1 (hr) 2008-07-24 2012-08-31 Nerviano Medical Sciences S.R.L. 3,4-diarilpirazoli kao inhibitori proteinskih kinaza
EP2326622A1 (en) 2008-07-28 2011-06-01 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
CA2738448A1 (en) 2008-09-29 2010-04-01 Boehringer Ingelheim International Gmbh New chemical compounds
CN102238945B (zh) 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
WO2010056662A1 (en) 2008-11-11 2010-05-20 University Of Washington Activated wnt-beta-catenin signaling in melanoma
JP5490137B2 (ja) 2008-12-19 2014-05-14 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ プロテインキナーゼ阻害薬としての二環式ピラゾール
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
RU2402602C1 (ru) * 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
JP5789602B2 (ja) 2009-06-15 2015-10-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピリミジニルピロロピリジノン誘導体、これらの製造のための方法およびキナーゼ阻害剤としてのこれらの使用
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
BR112012017705B1 (pt) 2010-01-27 2020-03-24 Nerviano Medical Science S.R.L. Derivados de sulfonamidas de 3,4-diarilpirazóis como inibidores da proteína cinase
RU2639876C2 (ru) 2010-03-30 2017-12-25 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
WO2012016993A1 (en) 2010-08-03 2012-02-09 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
CN103442715A (zh) 2011-03-21 2013-12-11 瓦尔库里亚公司 包括hdac抑制剂以及类固醇的药用组合物及其用途
SG195141A1 (en) 2011-06-14 2013-12-30 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer suchas a myeloproliferative neoplasm
PE20141994A1 (es) 2011-11-23 2014-12-24 Novartis Ag Formulaciones farmaceuticas
AU2013343425A1 (en) 2012-11-08 2015-06-11 Novartis Ag Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases

Also Published As

Publication number Publication date
AU2012335663A1 (en) 2014-05-29
BR112014011223A2 (pt) 2017-05-09
JP6150813B2 (ja) 2017-06-21
JP2014533272A (ja) 2014-12-11
US20140275136A1 (en) 2014-09-18
RU2014117707A (ru) 2015-12-20
MX2014005726A (es) 2014-05-28
EP2776037B1 (en) 2019-01-09
CN108542906A (zh) 2018-09-18
EP2776037A1 (en) 2014-09-17
BR112014011223A8 (pt) 2023-01-31
WO2013070996A1 (en) 2013-05-16
AU2012335663B2 (en) 2015-12-24
CA2855243C (en) 2020-04-14
CA2855243A1 (en) 2013-05-16
HK1198920A1 (en) 2015-06-19
US11007194B2 (en) 2021-05-18
RU2622015C2 (ru) 2017-06-08
CN103917236A (zh) 2014-07-09

Similar Documents

Publication Publication Date Title
MX2014005726A (es) Metodo de tratamiento de una enfermedad proliferativa.
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
MY170713A (en) Treatment protocol of diabetes type 2
PL2683395T3 (pl) Zastosowanie małych dawek il-2 do leczenia cukrzycy typu 1
MX360189B (es) Terapia de combinacion para el tratamiento de glioblastoma.
MX2014010481A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
EA201991484A1 (ru) Лекарственные формы энзалутамида
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
NZ732511A (en) Small molecule inhibitors of egfr and pi3k
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
BR112013024211A2 (pt) tratamento de tumores sólidos
PH12014501543A1 (en) Combination therapy for the treatment of ovarian cancer
PH12015500867A1 (en) Treatment of prostate cancer with tor kinase inhibitors
GEP201706655B (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
IN2014DN03464A (OSRAM)
MX343968B (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
PH12014502065A1 (en) Vesicular formulations
GB201102248D0 (en) Treatment of bipolar disorder
MX369774B (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
UY33973A (es) Métodos de tratamiento dirigido de degeneración lobular frontotemporal.
WO2012106473A8 (en) Dosing for treatment with anti-egfl7 antibodies
IN2014KN01772A (OSRAM)
IL229791A0 (en) Indoleamine derivatives for the treatment of diseases of the central nervous system
WO2014153505A3 (en) Treatment of chemotherapy-induced peripheral neuropathy
EA201591184A1 (ru) Применение пидотимода для лечения атопического дерматита

Legal Events

Date Code Title Description
FG Grant or registration